Wells Fargo’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-35,800
| Closed | -$1.33M | – | 7591 |
|
|
2023
Q4 | $1.33M | Buy |
+35,800
| New | +$1.29M | ﹤0.01% | 3235 |
|
|
2023
Q3 | – | Sell |
-3,300
| Closed | -$118K | – | 7613 |
|
|
2023
Q2 | $118K | Sell |
3,300
-900
| -21% | -$32.3K | ﹤0.01% | 4936 |
|
|
2023
Q1 | $149K | Buy |
4,200
+1,900
| +83% | +$66.5K | ﹤0.01% | 4596 |
|
|
2022
Q4 | $80.8K | Sell |
2,300
-23,700
| -91% | -$789K | ﹤0.01% | 4639 |
|
|
2022
Q3 | $765K | Buy |
26,000
+5,440
| +26% | +$206K | ﹤0.01% | 3411 |
|
|
2022
Q2 | $1.12M | Sell |
20,560
-80
| -0.4% | -$4.42K | ﹤0.01% | 3225 |
|
|
2022
Q1 | $1.12M | Sell |
20,640
-400,720
| -95% | -$21.8M | ﹤0.01% | 3784 |
|
|
2021
Q4 | $23.2M | Sell |
421,360
-2,160
| -0.5% | -$112K | 0.01% | 1227 |
|
|
2021
Q3 | $20.2M | Buy |
423,520
+76,000
| +22% | +$3.82M | ﹤0.01% | 1655 |
|
|
2021
Q2 | $17.3M | Sell |
347,520
-2,480
| -0.7% | -$119K | ﹤0.01% | 1782 |
|
|
2021
Q1 | $15.6M | Buy |
350,000
+19,120
| +6% | +$868K | ﹤0.01% | 1864 |
|
|
2020
Q4 | $2.49M | Buy |
330,880
+6,240
| +2% | +$287K | ﹤0.01% | 3334 |
|
|
2020
Q3 | $2.47M | Sell |
324,640
-38,400
| -11% | -$1.92M | ﹤0.01% | 3146 |
|
|
2020
Q2 | $2.01M | Buy |
363,040
+159,520
| +78% | +$8.18M | ﹤0.01% | 3261 |
|
|
2020
Q1 | $1.84M | Buy |
203,520
+81,520
| +67% | +$4.35M | ﹤0.01% | 3077 |
|
|
2019
Q4 | $150K | Buy |
122,000
+6,160
| +5% | +$343K | ﹤0.01% | 5116 |
|
|
2019
Q3 | $364K | Hold |
115,840
| – | – | ﹤0.01% | 4589 |
|
|
2019
Q2 | $572K | Buy |
115,840
+7,680
| +7% | +$385K | ﹤0.01% | 4283 |
|
|
2019
Q1 | $415K | Sell |
108,160
-273,760
| -72% | -$13.7M | ﹤0.01% | 4446 |
|
|
2018
Q4 | $201K | Buy |
381,920
+94,800
| +33% | +$4.67M | ﹤0.01% | 4900 |
|
|
2018
Q3 | $193K | Sell |
287,120
-1,200
| -0.4% | -$61K | ﹤0.01% | 5027 |
|
|
2018
Q2 | $339K | Buy |
288,320
+160,560
| +126% | +$8.09M | ﹤0.01% | 4722 |
|
|
2018
Q1 | $309K | Sell |
127,760
-581,040
| -82% | -$27.1M | ﹤0.01% | 4727 |
|
|
2017
Q4 | $1.8M | Hold |
708,800
| – | – | ﹤0.01% | 3445 |
|
|
2017
Q3 | $445K | Buy |
708,800
+80,000
| +13% | +$4.06M | ﹤0.01% | 4408 |
|
|
2017
Q2 | $373K | Hold |
628,800
| – | – | ﹤0.01% | 4405 |
|
|
2017
Q1 | $770K | Sell |
628,800
-279,200
| -31% | -$14.2M | ﹤0.01% | 3943 |
|
|
2016
Q4 | $4.14M | Buy |
908,000
+64,000
| +8% | +$3.16M | ﹤0.01% | 2552 |
|
|
2016
Q3 | $2.29M | Buy |
844,000
+240,000
| +40% | +$13.2M | ﹤0.01% | 2861 |
|
|
2016
Q2 | $2.23M | Buy |
604,000
+160,000
| +36% | +$8.43M | ﹤0.01% | 2888 |
|
|
2016
Q1 | $1.93M | Buy |
444,000
+144,400
| +48% | +$7.19M | ﹤0.01% | 2947 |
|
|
2015
Q4 | $1.28M | Hold |
299,600
| – | – | ﹤0.01% | 3321 |
|
|
2015
Q3 | $2.12M | Hold |
299,600
| – | – | ﹤0.01% | 2956 |
|
|
2015
Q2 | $1.38M | Buy |
299,600
+125,120
| +72% | +$7.04M | ﹤0.01% | 3360 |
|
|
2015
Q1 | $459K | Hold |
174,480
| – | – | ﹤0.01% | 4006 |
|
|
2014
Q4 | $900K | Hold |
174,480
| – | – | ﹤0.01% | 3582 |
|
|
2014
Q3 | $709K | Buy |
+174,480
| New | +$10.7M | ﹤0.01% | 3682 |
|
Other funds holding GSK
JEST
Wells Fargo's GSK Position: Q1 2026 in Review
Wells Fargo reduced its GSK (GSK) stake by 45% in Q1 2026, selling an estimated $61.3M and leaving 1,405,498 shares worth $77.6M. The position accounts for 0.01% of the portfolio, ranked #734.
Wells Fargo first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $521M in Q2 2016. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Wells Fargo held 1,405,498 shares of GSK worth $77.6M as of Q1 2026.
- Wells Fargo sold 1,130,352 GSK shares in Q1 2026, an estimated $61.3M.
- GSK made up 0.01% of Wells Fargo's portfolio in Q1 2026, its #734 holding.
- Wells Fargo first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
- Wells Fargo's GSK position peaked at $521M in Q2 2016.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.